Literature DB >> 35895181

Bcl-2 and Noxa are potential prognostic indicators for patients with gastroenteropancreatic neuroendocrine neoplasms.

Yu Guo1, Lin Zhang2,3,4, Ning Zhang1, Luohai Chen1, Qiuyun Luo2,3,5, Man Liu1, Dajun Yang6,7, Jie Chen8,9,10,11.   

Abstract

PURPOSE: Bcl-2 family proteins are of great significance in the pathogenesis and development of tumors. In this study, the correlations between the expression of Bcl-2 family proteins and clinicopathological features and prognosis of neuroendocrine neoplasms (NENs) were further investigated.
METHODS: 105 Patients diagnosed with gastroenteropancreatic NENs (GEP-NENs) with the paraffin specimen of the tumor available were retrospectively included. Immunohistochemistry (IHC) was performed to detect the expression of Bcl-2 family proteins in paraffin-embedded samples. Student's t-test and Chi-square test were applied to compare the difference of quantitative and categorical variables, respectively. Survival analysis was conducted according to Kaplan-Meier method. Univariate and multivariate cox regression analysis were used to identify the independent prognostic factors.
RESULTS: The IHC score of Bcl-2 was significantly higher in neuroendocrine carcinoma (NEC) patients (65.6%), while a higher IHC score of Noxa was more common in neuroendocrine tumor (NET) patients (49.3%). Survival analysis indicated that patients with higher Bcl-2 expression and lower Noxa expression had worse 5-year survival (39.3% vs. 75.6%, p < 0.001; 40.6% vs. 84.9%, p < 0.001). Multivariate cox analysis indicated that high Bcl-2 expression was an independent factor associated with inferior DFS (hazard ratio [HR]: 2.092; 95% confidence interval [CI]: 1.106-3.955; p = 0.023) and OS (HR: 2.784; 95% CI: 1.326-5.846; p = 0.007), while higher Noxa expression was associated with superior DFS (HR:0.398; 95% CI: 0.175-0.907; p = 0.028) and OS (HR: 0.274; 95% CI: 0.110-0.686; p = 0.006).
CONCLUSIONS: Higher expression of Bcl-2 and lower expression of Noxa were associated with unfavorable prognosis of GEP-NENs patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Apoptosis; Bcl-2; Neuroendocrine neoplasms; Noxa; prognosis

Mesh:

Year:  2022        PMID: 35895181     DOI: 10.1007/s12020-022-03114-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  2 in total

1.  bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways.

Authors:  T C Fisher; A E Milner; C D Gregory; A L Jackman; G W Aherne; J A Hartley; C Dive; J A Hickman
Journal:  Cancer Res       Date:  1993-07-15       Impact factor: 12.701

Review 2.  The Bcl-2 gene family and apoptosis.

Authors:  E M Bruckheimer; S H Cho; M Sarkiss; J Herrmann; T J McDonnell
Journal:  Adv Biochem Eng Biotechnol       Date:  1998       Impact factor: 2.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.